

**Silicon Laboratories Inc.**  
**Condensed Consolidated Statements of Operations**  
(In thousands, except per share data)  
(Unaudited)

	Three Months Ended		Year Ended	
	December 31, 2022	January 1, 2022	December 31, 2022	January 1, 2022
Revenues	\$ 257,325	\$ 208,680	\$ 1,024,106	\$ 720,860
Cost of revenues	100,028	80,849	381,549	295,468
Gross profit	157,297	127,831	642,557	425,392
Operating expenses:				
Research and development	86,649	71,705	332,326	273,208
Selling, general and administrative	46,573	53,487	190,971	185,022
Operating expenses	133,222	125,192	523,297	458,230
Operating income (loss)	24,075	2,639	119,260	(32,838)
Other income (expense):				
Interest income and other, net	4,299	2,595	13,915	5,696
Interest expense	(1,849)	(6,628)	(6,723)	(31,033)
Income (loss) from continuing operations before income taxes	26,525	(1,394)	126,452	(58,175)
Provision for income taxes	1,579	884	38,450	13,427
Equity-method earnings	415	7,791	3,400	13,728
Income (loss) from continuing operations	25,361	5,513	91,402	(57,874)
Income (loss) from discontinued operations, net of income taxes	--	(8,611)	--	2,175,273
Net income (loss)	\$ 25,361	\$ (3,098)	\$ 91,402	\$ 2,117,399
Basic earnings (loss) per share:				
Continuing operations	\$ 0.78	\$ 0.14	\$ 2.61	\$ (1.35)
Net income	\$ 0.78	\$ (0.08)	\$ 2.61	\$ 49.44
Diluted earnings (loss) per share:				
Continuing operations	\$ 0.76	\$ 0.13	\$ 2.54	\$ (1.35)
Net income	\$ 0.76	\$ (0.08)	\$ 2.54	\$ 47.78
Weighted-average common shares outstanding:				
Basic	32,542	38,965	35,086	42,830
Diluted	33,265	41,031	36,042	44,315

**Silicon Laboratories Inc.**  
**Condensed Consolidated Balance Sheets**  
(In thousands, except per share data)  
(Unaudited)

	<b>December 31, 2022</b>	<b>January 1, 2022</b>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 499,915	\$1,074,623
Short-term investments	692,024	964,582
Accounts receivable, net	71,437	98,313
Inventories	100,417	49,307
Prepaid expenses and other current assets	97,570	51,748
Total current assets	1,461,363	2,238,573
Property and equipment, net	152,016	146,516
Goodwill	376,389	376,389
Other intangible assets, net	84,907	118,978
Other assets, net	94,753	77,839
Total assets	\$2,169,428	\$2,958,295
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable	\$ 89,860	\$ 47,327
Current portion of convertible debt, net	--	450,599
Deferred revenue and returns liability	6,780	13,849
Other current liabilities	89,136	157,052
Total current liabilities	185,776	668,827
Convertible debt, net	529,573	--
Other non-current liabilities	49,071	77,044
Total liabilities	764,420	745,871
Commitments and contingencies		
Stockholders' equity:		
Preferred stock – \$0.0001 par value; 10,000 shares authorized; no shares issued	--	--
Common stock – \$0.0001 par value; 250,000 shares authorized; 31,994 and 38,481 shares issued and outstanding at December 31, 2022 and January 1, 2022, respectively	3	4
Retained earnings	1,415,693	2,214,839
Accumulated other comprehensive loss	(10,688)	(2,419)
Total stockholders' equity	1,405,008	2,212,424
Total liabilities and stockholders' equity	\$2,169,428	\$2,958,295

**Silicon Laboratories Inc.**  
**Condensed Consolidated Statements of Cash Flows**  
(In thousands)  
(Unaudited)

	<b>Year Ended</b>	
	<b>December 31, 2022</b>	<b>January 1, 2022</b>
<b>Operating Activities</b>		
Net income	\$ 91,402	\$2,117,399
Adjustments to reconcile net income to net cash provided by (used in) operating activities of continuing operations:		
Income from discontinued operations, net of income taxes	--	(2,175,273)
Depreciation of property and equipment	22,524	18,051
Amortization of other intangible assets	34,071	44,505
Amortization of debt discount and debt issuance costs	2,003	22,767
Loss on extinguishment of convertible debt	3	3,370
Stock-based compensation expense	60,510	56,842
Equity-method earnings	(3,400)	(13,728)
Deferred income taxes	(18,240)	(3,414)
Changes in operating assets and liabilities:		
Accounts receivable	26,876	(3,144)
Inventories	(51,044)	(1,510)
Prepaid expenses and other assets	(31,240)	44,664
Accounts payable	36,797	(7,704)
Other current liabilities and income taxes	(12,738)	2,109
Deferred revenue and returns liability	(7,069)	863
Other non-current liabilities	(9,181)	(14,599)
Net cash provided by operating activities of continuing operations	141,274	91,198
<b>Investing Activities</b>		
Purchases of marketable securities	(607,237)	(1,541,971)
Sales of marketable securities	223,354	250,075
Maturities of marketable securities	650,946	844,966
Purchases of property and equipment	(26,525)	(28,577)
Purchases of other assets	--	(1,158)
Net cash provided by (used in) investing activities of continuing operations	240,538	(476,665)
<b>Financing Activities</b>		
Payments on debt	(21)	(140,572)
Repurchases of common stock	(883,424)	(1,150,044)
Payment of taxes withheld for vested stock awards	(15,387)	(22,239)
Proceeds from the issuance of common stock	11,779	14,183
Net cash used in financing activities of continuing operations	(887,053)	(1,298,672)
<b>Discontinued Operations</b>		
Operating activities	(69,467)	(191,642)
Investing activities	--	2,747,684
Net cash provided by (used in) discontinued operations	(69,467)	2,556,042
Increase (decrease) in cash and cash equivalents	(574,708)	871,903
Cash and cash equivalents at beginning of period	1,074,623	202,720
Cash and cash equivalents at end of period	<u>\$ 499,915</u>	<u>\$1,074,623</u>

## Non-GAAP Financial Measurements

In addition to the GAAP results provided throughout this document, Silicon Labs has provided non-GAAP financial measurements on a basis excluding non-cash and other charges and benefits. Details of these excluded items are presented in the tables below, which reconcile the GAAP results to non-GAAP financial measurements.

The non-GAAP financial measurements do not replace the presentation of Silicon Labs' GAAP financial results. These measurements provide supplemental information to assist management and investors in analyzing Silicon Labs' financial position and results of operations. Silicon Labs has chosen to provide this information to investors to enable them to perform meaningful comparisons of past, present and future operating results and as a means to emphasize the results of core on-going operations.

### Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data)

Non-GAAP Income Statement Items	Three Months Ended December 31, 2022						
	GAAP Measure	GAAP Percent of Revenue	Stock Compensation Expense	Intangible Asset Amortization	Termination Costs & Other	Non- GAAP Measure	Non-GAAP Percent of Revenue
Revenues	\$257,325						
Gross profit	157,297	61.1%	\$318	\$ --	\$ --	\$157,615	61.3%
Research and development	86,649	33.7%	9,378	6,724	873	69,674	27.1%
Selling, general and administrative	46,573	18.1%	7,601	19	(279)	39,232	15.2%
Operating expenses	133,222	51.8%	16,979	6,743	594	108,906	42.3%
Operating income	24,075	9.4%	17,297	6,743	594	48,709	18.9%

  

Non-GAAP Earnings Per Share and Income Tax Rate	Three Months Ended December 31, 2022								
	GAAP Measure	GAAP Tax Percentage Rate	Stock Compensation Expense	Intangible Asset Amortization	Termination Costs & Other	Equity-Method Investment Adjustments	Income Tax Adjustments	Non- GAAP Measure	Non-GAAP Tax Percentage Rate
Income before income taxes and equity-method earnings	\$26,940		\$17,297	\$6,743	\$594	\$(414)	\$ --	\$51,160	
Provision for income taxes	1,579	5.9%					6,047	7,626	14.9%
Net income	\$25,361							\$43,534	
Diluted shares outstanding	33,265							33,265	
Diluted earnings per share	\$ 0.76							\$ 1.31	

**Unaudited Forward-Looking Statements Regarding Business Outlook\*\***  
**(In millions, except per share data)**

<b>Business Outlook</b>	<b>Three Months Ending April 1, 2023</b>		
	<b>GAAP Measure</b>	<b>Non-GAAP Adjustments*</b>	<b>Non-GAAP Measure</b>
Gross margin	63%	0%	63%
Operating expenses	\$139	\$(28)	\$111
Effective tax rate	31%	(8)%	23%
Diluted earnings per share - low	\$0.36	\$0.71	\$1.07
Diluted earnings per share - high	\$0.46	\$0.71	\$1.17

\* Non-GAAP adjustments include the following estimates: stock compensation expense of \$16.6 million, intangible asset amortization of \$6.5 million, termination costs of \$5.4 million, and the associated tax impact from the aforementioned items.

\*\* These financial schedules contain forward-looking statements based on Silicon Labs' current expectations. The words "believe," "estimate," "expect," "intend," "anticipate," "plan," "project," "will" and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Silicon Labs and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: the competitive and cyclical nature of the semiconductor industry; the challenging macroeconomic environment; geographic concentration of manufacturers, assemblers, test service providers and customers in Asia that subjects Silicon Labs' business and results of operations to risks of natural disasters, epidemics or pandemics, war and political unrest; risks that demand and the supply chain may be adversely affected by military conflict (including between Russia and Ukraine), terrorism, sanctions or other geopolitical events globally (including conflict between Taiwan and China); risks that Silicon Labs may not be able to maintain its historical growth; quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with international activities (including trade barriers, particularly with respect to China); intellectual property litigation risks; risks associated with acquisitions and divestitures; product liability risks; difficulties managing and/or obtaining sufficient supply from Silicon Labs' distributors, manufacturers and subcontractors; dependence on a limited number of products; absence of long-term commitments from customers; inventory-related risks; difficulties managing international activities; risks that Silicon Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; dependence on key personnel; stock price volatility; the impact of COVID-19 on the U.S. and global economy; debt-related risks; capital-raising risks; the timing and scope of anticipated share repurchases and/or dividends; average selling prices of products may decrease significantly and rapidly; information technology risks; cyber-attacks against Silicon Labs' products and its networks and other factors that are detailed in the SEC filings of Silicon Laboratories Inc. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. References in these financial schedules to Silicon Labs shall mean Silicon Laboratories Inc.